Growth Pattern and Final Height after Cessation of Gonadotropin-Suppressive Therapy in Girls with Central Sexual Precocity
Authors:
Open Access
- 1 September 2007
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (9) , 3483-3489
Abstract
Objective: The objective of the study was to determine whether height gain after discontinuation of gonadotropin-suppressive (GnRHa) therapy differs in girls with sexual precocity diagnosed at various ages and assess its influence on final height (FHt) outcome. Design: We compared data on post-GnRHa treatment course and FHt of 115 girls [22 diagnosed before chronological age of 6 yr; 38 between ages 6 and 8 yr; and 55 early fast puberty (EFP) between ages 8 and 9 yr] treated with GnRHa from Tanner stage 2–3 to chronological age 11–12 yr and bone age 12–12.5 yr. Results: Despite comparable bone age at cessation of treatment, similar time to resumption of puberty (0.6 ± 0.7, 0.5 ± 0.7, and 0.5 ± 0.7 yr), and age at menarche (12.6 ± 0.5, 12.6 ± 0.6, and 12.7 ± 0.9 yr), height gain from cessation of therapy to FHt was greater and time to epiphyseal fusion was longer in the younger central precocious puberty (CPP) than in the older CPP (P < 0.05) and EFP (P < 0.001) groups. The percentage of residual growth predicted at discontinuation of treatment was achieved only by the younger CPP (6.6 ± 1.6% vs. 6.7 ± 1.6%), whereas in older CPP and EFP, it was significantly lower (6.2 ± 1.6% vs. 4.6 ± 2.7% and 6.3 ± 1.5% vs. 3.6 ± 1.5%, respectively). FHt of these two groups was compromised, compared with FHt predicted at discontinuation of treatment (P < 0.01 and P < 0.001, respectively). Conclusions: Girls with sexual precocity diagnosed after the age of 6 yr exhibit earlier epiphyseal fusion with diminished posttreatment height gain and compromised FHt. Because recovery of gonadal axis was similar in all girls, differences were probably due to pretreatment intrinsic changes in the growth plate. Prediction of residual growth at discontinuation of treatment is unreliable in these girls.Keywords
This publication has 22 references indexed in Scilit:
- The relation between skeletal maturation and adiposity in African American and Caucasian childrenThe Journal of Pediatrics, 2001
- Effects of estrogen on growth plate senescence and epiphyseal fusionProceedings of the National Academy of Sciences, 2001
- The Estrogen Receptor β-Isoform (ERβ) of the Human Estrogen Receptor Modulates ERα Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens1Endocrinology, 1999
- Lack of Effect of GnRH Agonists on Final Height in Girls with Advanced Puberty: A Randomized Long-Term Pilot StudyThe Journal of Clinical Endocrinology & Metabolism, 1999
- Final Height of Girls with Central Precocious Puberty, Untreated versus Treated with Cyproterone Acetate or GnRH AnalogueHormone Research, 1997
- Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.Archives of Disease in Childhood, 1996
- Pubertal Development, Growth and Final Height in Girls with Sexual Precocity after Therapy with the GnRH Analogue D-TRP-6-LHRHHormone Research, 1990
- Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche.Journal of Clinical Investigation, 1986
- Standards for Children's Height at Ages 2-9 Years Allowing for Height of ParentsArchives of Disease in Childhood, 1970
- Variations in pattern of pubertal changes in girls.Archives of Disease in Childhood, 1969